News HP

• Efficacy and safety are consistently demonstrated in several in vivo preclinical models
• Anti-CD160 is a potent inhibitor of ocular v

• NOVA awarded €2.4 million to leverage Jinkō®, its best-in-class clinical trial simulation platform, to conduct in silico studie

• The Biologics License Application (BLA) will be revie

Thanks to acquisition, the Italian pharmaceutical Group strengthens its commitment to Research & Development in Oncology, and consolidate its

• The French National Agency for the Medicines and Health Products Safety (ANSM) granted a Temporary Authorisation for Use (ATU) so-called

In 2015, the single interministerial fund (FUI) approved the TYROMAB (TYROsine kinase receptor Monoclonal AntiBody) project, led by a consortium o

Elsalys Biotech SAS, a 2013 spinout from Transgene SA, achieved a significant milestone with the finding that lead candidate inolimomab (Leukotac)

• Follow-up of INO-107 Phase III study patients up to 8.5 years is the first long term analysis of a randomized study in acute steroid-r

Visit JP Morgan's Website

Dr Thierry Menguy, PhD, Head of mAb Development and Production Unit and co-founder of ELSALYS BIOTECH, has presented "Anti-CD160 alone or in combin